LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Strona główna・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

41.9 0.14

Buy Sell

Overview

Share price change

24h

Current

Min

41.01

Max

42.01

Key metrics
By Trading Economics
Income	-14M -105M
Profit margin	-867.293
Employees	316
EBITDA	-15M -104M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.98% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-13M 3.3B
Previous open	41.76
Previous close	41.9

News Sentiment

By Acuity

25%

75%

58 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

34.81 / 38.24 Support & Resistance

Xenon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 mar 2026, 19:32 UTC

Acquisitions, Mergers, Takeovers

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mar 2026, 22:26 UTC

Major News Events

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar 2026, 22:07 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar 2026, 21:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

6 mar 2026, 21:37 UTC

Earnings

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar 2026, 21:25 UTC

Major News Events

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar 2026, 21:17 UTC

Earnings

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar 2026, 20:50 UTC

Earnings

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar 2026, 20:46 UTC

Earnings

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar 2026, 20:31 UTC

Major News Events

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar 2026, 20:12 UTC

Market Talk

Major News Events

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar 2026, 19:10 UTC

Market Talk

Major News Events

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar 2026, 18:44 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar 2026, 18:08 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mar 2026, 17:46 UTC

Major News Events

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mar 2026, 17:40 UTC

Market Talk

Earnings

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mar 2026, 17:40 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 17:32 UTC

Market Talk

Major News Events

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mar 2026, 17:28 UTC

Market Talk

Major News Events

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mar 2026, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

6 mar 2026, 17:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

6 mar 2026, 17:20 UTC

Acquisitions, Mergers, Takeovers

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

32.98% upside

12 Months Forecast

Average 55.92 USD 32.98%

High 66 USD

Low 44 USD

Based on 15 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

34.81 / 38.24Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

58 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.